Akero Therapeutics Inc Stock News

We are still pretty early in the new year, but some companies are already delivering outsize returns to their shareholders. Akero Therapeutics (AKRO -2.31%)is part of this group.

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of (i) 6,427,170 shares of its common stock at a public offering ...

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 5,333,420 shares of its common stock at a public offering price of $48.00 pe...

Company's stock surged over 100% after positive 96-week results from its phase 2b SYMMETRY study using EFX to treat F4 compensated cirrhosis due to MASH patients. The company achieved a significant reversal of cirrhosis, with 39% of patients showing improvement compared to 15% on placebo, highlighting EFX's efficacy. Upcoming catalysts include phase 3 SYNCHRONY studies targeting F1-F3 and F2-F3...

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the propos...

Shares of Akero Therapeutics (AKRO) doubled Monday when the pharmaceutical firm that focuses on metabolic illnesses reported positive results from a study of its experimental treatment for liver disease.

Akero Therapeutics Inc (NASDAQ: AKRO) says its candidate treatment for a serious liver disease demonstrated exceptional safety and efficacy in a Phase 2b study.

Akero Therapeutics doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations. The post Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study appeared first on Investor's Business Daily.